Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics, Inc.    SRPT

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sarepta Therapeutics: 3Q Earnings Snapshot

11/05/2020 | 06:21pm EST

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $196.5 million in its third quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.50.

The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.89 per share.

The biopharmaceutical company posted revenue of $143.9 million in the period, surpassing Street forecasts. Seven analysts surveyed by Zacks expected $131.5 million.

Sarepta Therapeutics shares have climbed 12% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $145.15, a rise of 55% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about SAREPTA THERAPEUTICS, INC.
01/13SAREPTA THERAPEUTICS : How a collaboration in the lab led to a seat at the table..
PU
01/13SAREPTA THERAPEUTICS : Genevant Sciences Unveil Research Collaboration for Neuro..
MT
01/13Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration fo..
GL
01/12INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/12SAREPTA THERAPEUTICS : Citigroup Downgrades Sarepta Therapeutics to Neutral from..
MT
01/11SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regu..
AQ
01/11SAREPTA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Conf..
AQ
01/11SAREPTA THERAPEUTICS : UBS Cuts Sarepta Therapeutics to Neutral From Buy, PT to ..
MT
01/11ELI LILLY, TWITTER, NIO : What to Watch When the Stock Market Opens Today
DJ
01/09SRPT EQUITY ALERT : ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of S..
PR
More news
Financials (USD)
Sales 2020 530 M - -
Net income 2020 -516 M - -
Net cash 2020 823 M - -
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 7 127 M 7 127 M -
EV / Sales 2020 11,9x
EV / Sales 2021 9,20x
Nbr of Employees 743
Free-Float 95,2%
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 121,75 $
Last Close Price 90,32 $
Spread / Highest target 123%
Spread / Average Target 34,8%
Spread / Lowest Target -19,2%
EPS Revisions
Managers and Directors
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Wilsey Chairman
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS, INC.-47.02%7 127
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458